We are a research laboratory located in the McGill University campus.
Drug resistance remains a major clinical challenge for cancer therapy. Thus, a better understanding of resistance mechanisms is essential to enable the rational development of effective treatments. Using unbiased functional genetic screens, we aim to uncover novel genes and network interactions that modulate responses to cancer therapeutics and to help devise treatment strategies to overcome drug resistance.
Genotype-directed cancer therapeutics often target gain-of-function oncogenic mutations in cancer cells and thus have less side effects in normal tissue. However, some cancer driver mutations such as inactivation of tumour suppressors are not directly actionable. In this context, we use synthetic lethal approaches to uncover vulnerabilities of hard-to-treat cancer driver mutations that can be exploited therapeutically.